Funding will allow the company to bring novel technology that illuminates lung and ovarian cancer during surgery to more patients

资金将允许该公司为更多患者带来在手术期间照亮肺癌和卵巢癌的新技术

WEST LAFAYETTE, Ind., Nov. 16, 2023 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, today announced the completion of a $30 million Series C financing. This significant investment will play a pivotal role in accelerating the commercialization of the company's novel compound, CYTALUX, the only FDA approved molecular imaging agent that illuminates lung and ovarian cancer as an adjunct during surgery, enabling surgeons to detect more cancer for resection..

WEST LAFAYETTE，Ind。，2023年11月16日/PRNewswire/-On-Target Laboratories，Inc.，一家私营生物技术公司，开发术中分子成像剂，用于在手术过程中靶向和照亮癌症，今天宣布完成一项3000万美元的系列C融资。这项重大投资将在加速该公司新型化合物CYTALUX的商业化方面发挥关键作用，CYTALUX是唯一获得FDA批准的分子成像剂，可在手术过程中作为辅助手段照亮肺癌和卵巢癌，使外科医生能够检测更多癌症切除术。。

'This investment empowers us to accelerate the commercialization of our novel technology, further solidifying our position at the forefront of intraoperative molecular imaging,' said Ben Lundgren, President and CEO of On Target Laboratories. 'This financing is another vote of confidence in our mission to illuminate cancer intraoperatively so it can be removed completely.'.

“这项投资使我们能够加速我们新技术的商业化，进一步巩固我们在术中分子成像领域的地位，”目标实验室总裁兼首席执行官Ben Lundgren说这项融资是我们对术中阐明癌症的使命的另一个信心投票，以便可以完全消除癌症。

The funding was backed by new and existing investors H.I.G. Capital, The Hurvis Group, Johnson & Johnson Innovation – JJDC, Pension Fund of the Christian Church, 3B Future Health Fund, Elevate Ventures, and Olympus Innovation Ventures.

该资金得到了新的和现有的投资者H.I.G.Capital，Hurvis Group，Johnson＆Johnson Innovation-JJDC，基督教教会的养老金基金，3B未来健康基金，Elevate Ventures和Olympus Innovation Ventures的支持。

'On Target Laboratories is at the forefront of a new wave of fluorescent agents that are game changers for surgical imaging,' said Nacho Abia, Chief Strategy Officer at Olympus. 'The ability of CYTALUX to illuminate lung and ovarian cancer during surgery is a stellar example of what we describe at Olympus as 'making the invisible visible'.'.

奥林巴斯首席战略官Nacho Abia说：“目标实验室处于新一波荧光剂的前沿，这些荧光剂是外科成像的游戏改变者。”CYTALUX在手术过程中照射肺癌和卵巢癌的能力是我们在奥林巴斯描述为“使隐形可见”的一个很好的例子。

This infusion of capital will enable On Target Laboratories to expedite the commercial launch of CYTALUX and amplify its market presence, ultimately benefiting patients and healthcare providers across the United States.

这种资金注入将使目标实验室能够加快CYTALUX的商业推出并扩大其市场存在，最终使美国的患者和医疗保健提供者受益。

'This financing serves as a testament to the strength of On Target Laboratories' technology, especially in light of the complexities posed by the current financial landscape,' said Gwen Watanabe, Managing Director of H.I.G. BioHealth Partners and On Target Laboratories Board Member. 'We are delighted to see the support from both private equity and strategic investors as we introduce CYTALUX to the cancer community.'.

H.I.G.生物卫生合作伙伴和目标实验室董事会成员总经理Gwen Watanabe说：“这种融资证明了目标实验室技术的实力，特别是考虑到当前金融格局所带来的复杂性。”当我们将CYTALUX引入癌症社区时，我们很高兴看到私募股权和战略投资者的支持。

In August, On Target Laboratories announced that the Centers for Medicare & Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for CYTALUX use in ovarian and lung cancer surgery. Under NTAP, CMS will provide hospitals with additional payment of up to 65 percent of the average cost of CYTALUX, which is expected to expand access of the technology to more patients..

8月份，目标实验室宣布，医疗保险和医疗补助服务中心（CMS）授予CYTALUX用于卵巢癌和肺癌手术的新技术附加付款（NTAP）。根据NTAP，CMS将为医院提供高达CYTALUX平均成本65%的额外支付，预计这将扩大该技术向更多患者的使用。。

The closing of this funding round closely coincides with Stryker's recent introduction of the 1788 Platform, the only minimally invasive surgical camera currently cleared for use with CYTALUX. The convergence of Series C financing, NTAP reimbursement, and the nationwide rollout of this visualization solution creates a unique opportunity for On Target to expedite the expansion of CYTALUX..

这一轮资金的结束与Stryker最近推出的1788平台非常吻合，该平台是目前唯一被批准用于CYTALUX的微创手术相机。C系列融资，NTAP报销以及全国推出此可视化解决方案的融合为实现目标加速CYTALUX的扩张创造了独特的机会。。

About On Target Laboratories, Inc.

关于目标实验室公司。

On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Their molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, is comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells.

目标实验室发现并开发有针对性的术中分子成像剂，以在手术期间照亮癌症。他们的分子成像技术基于普渡大学药物发现总统学者Philip S.Low博士和拉尔夫C.Corley化学杰出教授的开创性工作，由近红外染料和靶向分子组成，或配体，其结合癌细胞上过表达的受体。

The imaging agents illuminate the cancerous tissue, which may enable surgeons to detect more cancer that otherwise may have been left behind..

成像剂照亮癌组织，这可能使外科医生能够检测到更多可能留下的癌症。。

CYTALUX, the company's first product, received FDA approval of a New Drug Application for ovarian cancer in November 2021 and a supplemental New Drug Application for lung cancer in December 2022. CYTALUX targets the folate receptors commonly found on many cancers, binds to the cancerous tissue, and illuminates under near-infrared light.

该公司的第一款产品CYTALUX于2021年11月获得FDA批准卵巢癌新药申请，并于2022年12月获得肺癌补充新药申请。CYTALUX靶向许多癌症中常见的叶酸受体，与癌组织结合，并在近红外光下照射。

A single dose of the agent is administered via intravenous infusion prior to surgery and assists surgeons in visually identifying additional cancerous tissue to be removed during the operation. For more information visit www.ontargetlabs.com and www.cytalux.com..

在手术前通过静脉内输注施用单剂量的药剂，并帮助外科医生在视觉上识别在手术期间要移除的另外的癌组织。欲了解更多信息，请访问www.ontargetlabs.com和www.cytalux.com。。

What is CYTALUX? CYTALUX is an FDA approved prescription medication that is given prior to surgery to adult patients who have ovarian cancer or known or suspected cancer in the lung. It helps surgeons visualize ovarian and lung cancer lesions during surgery.

什么是CYTALUX？CYTALUX是FDA批准的处方药，在手术前给予患有卵巢癌或已知或疑似肺癌的成年患者。它有助于外科医生在手术过程中观察卵巢癌和肺癌病变。

Important Safety InformationInfusion-Related ReactionsAdverse reactions including nausea, vomiting, abdominal pain, flushing, allergic reaction, elevation in blood pressure, indigestion, and chest discomfort were reported during the administration of CYTALUX. Your doctor may treat you with antihistamines and/or anti-nausea medication..

重要的安全信息输注相关反应在给予CYTALUX期间报告了不良反应，包括恶心，呕吐，腹痛，潮红，过敏反应，血压升高，消化不良和胸部不适。你的医生可能会用抗组胺药和/或抗恶心药治疗你。。

Risk of MisinterpretationErrors may occur with the use of CYTALUX. Sometimes cells may light up even if they are not cancerous or those that are cancerous may not light up. Also, non-cancerous cells from other areas may light up, such as areas of the bowel, kidneys, lymph nodes, lungs, and inflamed tissue..

使用CYTALUX可能会出现误解错误的风险。有时细胞可能会亮起，即使它们没有癌变，或者那些癌变的细胞可能不会亮起。此外，来自其他区域的非癌细胞可能会亮起，例如肠，肾，淋巴结，肺和发炎组织的区域。。

PregnancyCYTALUX may cause fetal harm when administered to a pregnant woman. There are no available human data to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Contact your healthcare provider with a known or suspected pregnancy..

怀孕Cytalux可能会对孕妇造成胎儿伤害。没有可用的人体数据来评估与药物相关的重大出生缺陷，流产或其他不良孕产妇或胎儿结局的风险。与您的医疗保健提供者联系，了解已知或疑似怀孕。。

Folate Supplementation UsageFolic acid may reduce the detection of cancerous tissue with CYTALUX. Patients should stop taking folate, folic acid, or folate-containing supplements 48 hours before administration of CYTALUX.

补充叶酸使用叶酸可能会减少CYTALUX对癌组织的检测。给予CYTALUX前48小时，患者应停止服用叶酸，叶酸或含叶酸的补充剂。

Adverse ReactionsThe most common side effects of CYTALUX reported in clinical trials were nausea (13%), vomiting (5%), abdominal pain (2%), flushing (2%), other infusion-related reactions (2%), allergic reaction (2%), elevation in blood pressure (1%), indigestion (1%), and chest discomfort (1%) during administration..

不良反应临床试验中报告的CYTALUX最常见的副作用是恶心（13%），呕吐（5%），腹痛（2%），潮红（2%），其他输液相关反应（2%），过敏反应（2%），给药期间血压升高（1%），消化不良（1%）和胸部不适（1%）。。

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CYTALUX. For more information, ask your healthcare provider.

如果您有任何困扰您或不会消失的副作用，请告诉您的医疗保健提供者。这些并不是CYTALUX所有可能的副作用。欲了解更多信息，请咨询您的医疗保健提供者。

Call your doctor for medical advice about side effects. You may report side effects to On Target Laboratories at 1-844-434-9333 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

打电话给你的医生，征求有关副作用的医疗建议。您可以在1-844-434-9333向目标实验室报告副作用，或在1-800-FDA-1088或www.FDA.gov/medwatch向FDA报告副作用。

See full Prescribing Information for more details.

有关详细信息，请参阅完整的处方信息。

SOURCE On Target Laboratories, Inc.

SOURCE On-Target Laboratories，Inc。